|
|
- Exposure–response analysis of adverse events associated with molibresib
and its active metabolites in patients with solid tumors Authors:
Anu Shilpa Krishnatry; Eva Hanze,
Tim Bergsma,
Arindam Dhar,
Marita Prohn,
Geraldine Ferron‐Brady Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 556-568, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12724 Issue No: Vol. 11, No. 5 (2022)
- Proarrhythmic risk assessment of drugs by dVm/dt shapes using the
convolutional neural network Authors:
Da Un Jeong; Yedam Yoo,
Aroli Marcellinus,
Ki‐Suk Kim,
Ki Moo Lim Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 653-664, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12803 Issue No: Vol. 11, No. 5 (2022)
- A novel cardiovascular systems model to quantify drugs effects on the
inter‐relationship between contractility and other hemodynamic variables Authors:
Yu Fu; Hadi Taghvafard,
Medhat M. Said,
Eric I. Rossman,
Teresa A. Collins,
Stéphanie Billiald‐Desquand,
Derek Leishman,
Piet H. Graaf,
J. G. Coen Hasselt,
Nelleke Snelder Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 640-652, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12774 Issue No: Vol. 11, No. 5 (2022)
- Using thrombocytopenia modeling to investigate the mechanisms underlying
platelet depletion induced by pan‐proteasome inhibitors Authors:
Floriane Lignet; Andreas D. Becker,
Claude Gimmi,
Felix Rohdich,
Samer El Bawab Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 594-603, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12743 Issue No: Vol. 11, No. 5 (2022)
- A semimechanistic population pharmacokinetic and pharmacodynamic model
incorporating autoinduction for the dose justification of TAS‐114 Authors:
Hikari Araki; Toru Takenaka,
Koichi Takahashi,
Fumiaki Yamashita,
Kazuaki Matsuoka,
Kunihiro Yoshisue,
Ichiro Ieiri Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 604-615, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12747 Issue No: Vol. 11, No. 5 (2022)
- A modeling‐based proposal for safe and efficacious reintroduction of
Authors:
Lina Keutzer; Yasamin Akhondipour Salehabad,
Lina Davies Forsman,
Ulrika S. H. Simonsson Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 628-639, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12768 Issue No: Vol. 11, No. 5 (2022)
- Quantitative systems pharmacology model‐based investigation of adverse
gastrointestinal events associated with prolonged treatment with PI3‐kinase inhibitors Authors:
Kapil Gadkar; Christina Friedrich,
Vincent Hurez,
Maria‐Luisa Ruiz,
Leslie Dickmann,
Mohit Kumar Jolly,
Leah Schutt,
Jin Jin,
Joseph A. Ware,
Saroja Ramanujan Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 616-627, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12749 Issue No: Vol. 11, No. 5 (2022)
- Erdafitinib’s effect on serum phosphate justifies its
pharmacodynamically guided dosing in patients with cancer Authors:
Anne‐Gaëlle Dosne; Elodie Valade,
Kim Stuyckens,
Peter De Porre,
Anjali Avadhani,
Anne O’Hagan,
Lilian Y. Li,
Daniele Ouellet,
Ruben Faelens,
Quentin Leirens,
Italo Poggesi,
Juan Jose Perez Ruixo Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 569-580, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12727 Issue No: Vol. 11, No. 5 (2022)
- Semimechanistic models to relate noxious stimulation, movement, and
pupillary dilation responses in the presence of opioids Authors:
Nicolás Marco‐Ariño; Sergio Vide,
Mercè Agustí,
Andrew Chen,
Sebastián Jaramillo,
Itziar Irurzun‐Arana,
Adrià Pacheco,
Carmen Gonzalez,
Erik W. Jensen,
Patricia Capsi‐Morales,
José F. Valencia,
Iñaki F. Troconiz,
Pedro L. Gambus,
Merlin D. Larson Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 581-593, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12729 Issue No: Vol. 11, No. 5 (2022)
- Challenges faced when modeling clinical toxicology and toxinology events
Authors:
Stephen Duffull; Geoff Isbister Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 532-534, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12792 Issue No: Vol. 11, No. 5 (2022)
- Addressing drug safety of maternal therapy during breastfeeding using
physiologically‐based pharmacokinetic modeling Authors:
Xian Pan; Karen Rowland Yeo Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 535-539, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12802 Issue No: Vol. 11, No. 5 (2022)
- Quantitative approaches to drug safety: The 2022 PSP special issue
Authors:
Eric A. Sobie
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 529-531, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12804 Issue No: Vol. 11, No. 5 (2022)
- Issue Information
Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 525-528, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12652 Issue No: Vol. 11, No. 5 (2022)
- Advancing drug safety science by integrating molecular knowledge with
post‐marketing adverse event reports Authors:
Theodoros G. Soldatos; Sarah Kim,
Stephan Schmidt,
Lawrence J. Lesko,
David B. Jackson Abstract: CPT: Pharmacometrics & Systems Pharmacology, Volume 11, Issue 5, Page 540-555, May 2022. PubDate: 2022-05-22T12:00:00-07:00 DOI: 10.1002/psp4.12765 Issue No: Vol. 11, No. 5 (2022)
- Multi‐phase Multi‐Layer Mechanistic Dermal Absorption (MPML MechDermA)
Model to predict local and systemic exposure of drug products applied on skin Authors:
Nikunjkumar Patel; James F. Clarke,
Farzaneh Salem,
Tariq Abdulla,
Frederico Martins,
Sumit Arora,
Eleftheria Tsakalozou,
Arran Hodgkinson,
Omid Arjmandi‐Tash,
Sinziana Cristea,
Priyanka Ghosh,
Khondoker Alam,
Sam G. Raney,
Masoud Jamei,
Sebastian Polak Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-06-07T02:06:34-07:00 DOI: 10.1002/psp4.12814
- Tutorial: Evaluation of Covariate Effects using Forest Plots and
Introduction to the coveffectsplot R package Authors:
J. F. Marier; Nathan Teuscher,
Mohamad‐Samer Mouksassi Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-06-07T02:06:28-07:00 DOI: 10.1002/psp4.12829
- Robust physiologically based pharmacokinetic model of rifampicin for
predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney Authors:
Ryuta Asaumi; Ken‐ichi Nunoya,
Yoshiyuki Yamaura,
Kunal S. Taskar,
Yuichi Sugiyama Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-06-06T05:45:02-07:00 DOI: 10.1002/psp4.12807
- Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in
Authors:
Stefan Willmann; Ibrahim Ince,
Maurice Ahsman,
Katrin Coboeken,
Yang Zhang,
Kirstin Thelen,
Dagmar Kubitza,
Peter Zannikos,
Wangda Zhou,
Liza Miriam Pina,
Teun Post,
Jörg Lippert Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-06-05T11:24:34-07:00 DOI: 10.1002/psp4.12830
- The area under the effect curve as an efficacy determinant for
anti‐infectives Authors:
Chao Chen; Silvia Maria Lavezzi,
Laura Iavarone Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-31T01:39:10-07:00 DOI: 10.1002/psp4.12811
- Deep compartment models: A deep learning approach for the reliable
prediction of time‐series data in pharmacokinetic modeling Authors:
Alexander Janssen; Frank W. G. Leebeek,
Marjon H. Cnossen,
Ron A. A. Mathôt,
for the OPTI‐CLOT study group SYMPHONY consortium,
K. Fijnvandraat,
M. Coppens,
K. Meijer,
S. E. M. Schols,
H. C. J. Eikenboom,
R. E. G. Schutgens,
E. A. M. Beckers,
P. Ypma,
M. J. H. A. Kruip,
S. Polinder,
R. Y. J. Tamminga,
P. Brons,
K. Fischer,
K. P. M. Galen,
L. Nieuwenhuizen,
M. H. E. Driessens,
I. Vliet,
J. Lock,
H. C. A. M. Hazendonk,
I. Moort,
J. M. Heijdra,
M. H. J. Goedhart,
W. Al Arashi,
T. Preijers,
N. C. B. Jager,
L. H. Bukkems,
M. E. Cloesmeijer,
P. W. Collins,
R. Liesner,
P. Chowdary,
C. M. Millar,
D. Hart,
D. Keeling Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-27T02:40:01-07:00 DOI: 10.1002/psp4.12808
- Population Pharmacokinetic Model for Once Daily Intravenous Busulfan in
Paediatric Subjects Describing Time‐Associated Clearance Authors:
Rachael Lawson; Christine E. Staatz,
Christopher J. Fraser,
Shanti Ramachandran,
Lochie Teague,
Richard Mitchell,
Tracey O’Brien,
Stefanie Hennig Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-05-25T05:13:36-07:00 DOI: 10.1002/psp4.12809
- Quantitative system pharmacology as a legitimate approach to examine
extrapolation strategies used to support pediatric drug development Authors:
Karim Azer; Jeffrey S. Barrett Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-24T02:51:21-07:00 DOI: 10.1002/psp4.12801
- Evaluation of drug–drug interaction potential for pemigatinib using
physiologically based pharmacokinetic modeling Authors:
Tao Ji; Xuejun Chen,
Swamy Yeleswaram Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-23T09:28:02-07:00 DOI: 10.1002/psp4.12805
- Machine learning algorithms to estimate everolimus exposure trained on
simulated and patient pharmacokinetic profiles Authors:
Marc Labriffe; Jean‐Baptiste Woillard,
Jean Debord,
Pierre Marquet Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-22T10:23:54-07:00 DOI: 10.1002/psp4.12810
- Population Pharmacokinetic/Pharmacodynamic Joint Modeling of Ixazomib
Efficacy and Safety Using Data from the Pivotal Phase 3 TOURMALINE‐MM1 Study in Multiple Myeloma Patients Authors:
Jaydeep K. Srimani; Paul M. Diderichsen,
Michael J. Hanley,
Karthik Venkatakrishnan,
Richard Labotka,
Neeraj Gupta Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-05-22T04:28:23-07:00 DOI: 10.1002/psp4.12815
- Modeling the bacterial dynamics in the gut microbiota following an
antibiotic‐induced perturbation Authors:
Jinju Guk; Antoine Bridier‐Nahmias,
Mélanie Magnan,
Nathalie Grall,
Xavier Duval,
Olivier Clermont,
Etienne Ruppé,
Camille d'Humières,
Olivier Tenaillon,
Erick Denamur,
France Mentré,
Jérémie Guedj,
Charles Burdet,
for the CEREMI study group Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-18T04:41:10-07:00 DOI: 10.1002/psp4.12806
- Introduction of an artificial neural network–based method for
concentration‐time predictions Authors:
Dominic Stefan Bräm; Neil Parrott,
Lucy Hutchinson,
Bernhard Steiert Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-18T01:50:14-07:00 DOI: 10.1002/psp4.12786
- Flexible and efficient Bayesian pharmacometrics modeling using Stan and
Torsten, Part I Authors:
Charles C. Margossian; Yi Zhang,
William R. Gillespie Abstract: CPT: Pharmacometrics & Systems Pharmacology, Accepted Article. PubDate: 2022-05-15T08:49:35-07:00 DOI: 10.1002/psp4.12812
- Population pharmacokinetics for oral paclitaxel in patients with
advanced/metastatic solid tumors Authors:
Jimmy He; Christopher G. C. A. Jackson,
Sanjeev Deva,
Tak Hung,
Katriona Clarke,
Eva Segelov,
Tsu‐Yi Chao,
Ming‐Shen Dai,
Hsien‐Tang Yeh,
Wen Wee Ma,
Douglas Kramer,
Wing‐Kai Chan,
Rudolf Kwan,
David Cutler,
Jay Zhi Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-10T09:44:06-07:00 DOI: 10.1002/psp4.12799
- Predicting disease activity in patients with multiple sclerosis: An
explainable machine‐learning approach in the Mavenclad trials Authors:
Sreetama Basu; Alain Munafo,
Ali‐Frederic Ben‐Amor,
Sanjeev Roy,
Pascal Girard,
Nadia Terranova Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-09T12:33:58-07:00 DOI: 10.1002/psp4.12796
- Quantitative systems pharmacology modeling provides insight into
inter‐mouse variability of Anti‐CTLA4 response Authors:
Wenlian Qiao; Lin Lin,
Carissa Young,
Jatin Narula,
Fei Hua,
Andrew Matteson,
Andrea Hooper,
Lore Gruenbaum,
Alison Betts Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-08T10:25:12-07:00 DOI: 10.1002/psp4.12800
- Development and application of a pediatric mechanistic kidney model
Authors:
Farzaneh Salem; Ben G. Small,
Trevor N. Johnson Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-04T01:34:49-07:00 DOI: 10.1002/psp4.12798
- Use of physiologically‐based pharmacokinetic modeling to inform dosing
of the opioid analgesics fentanyl and methadone in children with obesity Authors:
Jacqueline G. Gerhart; Fernando O. Carreño,
Jennifer L. Ford,
Andrea N. Edginton,
Eliana M. Perrin,
Kevin M. Watt,
William J. Muller,
Andrew M. Atz,
Amira Al‐Uzri,
Paula Delmore,
Daniel Gonzalez, on behalf of the
Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee,
Daniel K. Benjamin,
Christoph Hornik,
Kanecia Zimmerman,
Phyllis Kennel,
Rose Beci,
Chi Dang Hornik,
Gregory L. Kearns,
Matthew Laughon,
Ian M. Paul,
Janice Sullivan,
Kelly Wade,
Paula Delmore,
Perdita Taylor‐Zapata,
June Lee,
Ravinder Anand,
Gaurav Sharma,
Gina Simone,
Kim Kaneshige,
Lawrence Taylor,
Amira Al‐Uzri,
Chi Hornik,
Gregory Sokol,
David Speicher,
Janice Sullivan,
Peter Mourani,
Susan Mendley,
Marisa Meyer,
Robert Atkins,
Joseph Flynn,
Janelle Vaughns,
Catherine Sherwin,
Paula Delmore,
Stuart Goldstein,
Mobeen Rathore,
Chiara Melloni,
William Muller,
Paula Delmore,
Adriana Tremoulet,
Laura James,
Susan Mendley,
Martha Blackford,
Andrew Atz,
Michelle Adu‐Darko,
Peter Mourani,
Kevin Watt,
Chi Hornik,
Amira Al‐Uzri,
Janice Sullivan,
Matthew Laughon,
P. Brian Smith,
Kevin Watt,
Ira Cheifetz,
Andrew Atz,
Varsha Bhatt‐Mehta,
Allison Fernandez,
Jennifer Lowry Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-05-02T01:30:17-07:00 DOI: 10.1002/psp4.12793
- Finding the right hazard function for time‐to‐event modeling: A
tutorial and Shiny application Authors:
Rob C. Wijk; Ulrika S. H. Simonsson Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-28T10:48:53-07:00 DOI: 10.1002/psp4.12797
- Prediction of CYP‐mediated DDIs involving inhibition: Approaches to
Authors:
Peter J. Kilford; Kuan‐Fu Chen,
Kim Crewe,
Iain Gardner,
Oliver Hatley,
Alice Ban Ke,
Sibylle Neuhoff,
Mian Zhang,
Karen Rowland Yeo Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-28T01:14:21-07:00 DOI: 10.1002/psp4.12794
- Population PBPK modeling using parametric and nonparametric methods of the
Simcyp Simulator, and Bayesian samplers Authors:
Janak R. Wedagedera; Anthonia Afuape,
Siri Kalyan Chirumamilla,
Hiroshi Momiji,
Robert Leary,
Mike Dunlavey,
Richard Matthews,
Khaled Abduljalil,
Masoud Jamei,
Frederic Y. Bois Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-22T04:55:41-07:00 DOI: 10.1002/psp4.12787
- Model‐informed drug development of voxelotor in sickle cell disease:
Exposure‐response analysis to support dosing and confirm mechanism of action Authors:
Michelle L. Green; Radojka M. Savic,
Margaret Tonda,
Karin Jorga,
Carla B. Washington Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-21T12:33:33-07:00 DOI: 10.1002/psp4.12780
- Model‐informed drug development of voxelotor in sickle cell disease:
Population pharmacokinetics in whole blood and plasma Authors:
Radojka M. Savic; Michelle L. Green,
Karin Jorga,
Michael Zager,
Carla B. Washington Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-21T12:30:03-07:00 DOI: 10.1002/psp4.12731
- Quantitative methods and modeling to assess COVID‐19‐interrupted in
vivo pharmacokinetic bioequivalence studies with two reference batches Authors:
Yuqing Gong; Kairui Feng,
Peijue Zhang,
Jieon Lee,
Yuzhuo Pan,
Zhen Zhang,
Zhanglin Ni,
Tao Bai,
Miyoung Yoon,
Bing Li,
Carol Y. Kim,
Lanyan Fang,
Liang Zhao Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-20T04:29:02-07:00 DOI: 10.1002/psp4.12795
- Guide to development of compound files for PBPK modeling in the Simcyp
population‐based simulator Authors:
Udoamaka Ezuruike; Mian Zhang,
Amita Pansari,
Mailys De Sousa Mendes,
Xian Pan,
Sibylle Neuhoff,
Iain Gardner Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-18T09:54:31-07:00 DOI: 10.1002/psp4.12791
- A quantitative approach to the choice of number of samples for percentile
estimation in bootstrap and visual predictive check analyses Authors:
E. Niclas Jonsson; Joakim Nyberg Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-17T11:54:59-07:00 DOI: 10.1002/psp4.12790
- Exposure‐response analyses for selection/confirmation of optimal
isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma Authors:
Fatiha Rachedi; Kimiko Koiwai,
Nadia Gaudel‐Dedieu,
Bernard Sebastien,
Hoai‐Thu Thai,
Claire Brillac,
Jean Baptiste Fau,
Laurent Nguyen,
Helgi van de Velde,
Christine Veyrat‐Follet,
Dorothée Semiond Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-17T11:29:06-07:00 DOI: 10.1002/psp4.12789
- Population pharmacokinetics of mobocertinib in healthy volunteers and
patients with non–small cell lung cancer Authors:
Neeraj Gupta; Philippe B. Pierrillas,
Michael J. Hanley,
Steven Zhang,
Paul M. Diderichsen Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-11T11:24:05-07:00 DOI: 10.1002/psp4.12785
- Perspectives on training quantitative systems pharmacologists
Authors:
Tongli Zhang; Carolyn R. Cho,
Peter L. Bonate Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-07T01:09:01-07:00 DOI: 10.1002/psp4.12783
- Optimized sampling to estimate vancomycin drug exposure: Comparison of
pharmacometric and equation‐based approaches in a simulation‐estimation study Authors:
David W. Uster; Sebastian G. Wicha Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-05T10:49:09-07:00 DOI: 10.1002/psp4.12782
- PK/PD modeling links accelerated resolution of COVID‐19‐related
clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together Authors:
C. Steven Ernest; Jenny Y. Chien,
Dipak R. Patel,
Emmanuel Chigutsa Abstract: CPT: Pharmacometrics & Systems Pharmacology, EarlyView. PubDate: 2022-04-05T10:12:45-07:00 DOI: 10.1002/psp4.12784
|